Sun Pharmaceutical Industries Ltd: Valuation Shift Signals Changing Price Attractiveness

Valuation Metrics and Their Implications

As of 19 May 2026, Sun Pharma’s P/E ratio stands at 37.65, a level that categorises the stock as very expensive compared to its own historical range and sector benchmarks. This is a significant elevation from prior valuations, signalling that investors are currently willing to pay a premium for the company’s earnings. The price-to-book value ratio has also risen to 5.87, reinforcing the perception of heightened valuation levels. These figures contrast with the company’s previous valuation grade of expensive, now upgraded to very expensive as of 18 May 2026.

Other valuation multiples further illustrate this trend. The enterprise value to EBITDA (EV/EBITDA) ratio is at 24.84, and the enterprise value to EBIT (EV/EBIT) ratio is 29.62, both indicating a premium valuation relative to earnings before interest, taxes, depreciation, and amortisation. The PEG ratio, which adjusts the P/E ratio for earnings growth, is notably elevated at 12.78, suggesting that the stock’s price growth expectations are very high compared to its earnings growth trajectory.

Despite these lofty valuations, Sun Pharma continues to demonstrate robust operational performance. The company’s return on capital employed (ROCE) is a strong 25.07%, and return on equity (ROE) stands at 14.84%, reflecting efficient capital utilisation and profitability. Dividend yield remains modest at 0.87%, consistent with a growth-oriented large-cap pharmaceutical company.

Comparative Analysis with Peers

When compared with key peers in the Pharmaceuticals & Biotechnology sector, Sun Pharma’s valuation remains elevated but not unprecedented. Divi’s Laboratories and Torrent Pharmaceuticals are also rated very expensive, with P/E ratios of 71.42 and 64.45 respectively, and EV/EBITDA multiples of 52.41 and 36.18. Cipla, meanwhile, is classified as expensive with a P/E of 28.19 and EV/EBITDA of 18.17, while Dr Reddy’s Laboratories is considered fairly valued with a P/E of 26.44 and EV/EBITDA of 17.28.

This peer comparison highlights that while Sun Pharma’s valuation is high, it remains more moderate than some of its sector counterparts. The elevated PEG ratio, however, suggests that the market is pricing in a more aggressive growth outlook for Sun Pharma relative to its peers, which may or may not be justified depending on future earnings performance.

Price Performance and Market Context

Sun Pharma’s current market price is ₹1,905.20, having risen 1.34% on the day, with a high of ₹1,911.95 and a low of ₹1,865.00. The stock is trading near its 52-week high of ₹1,911.95, indicating strong recent momentum. Over the past week, the stock has gained 1.75%, outperforming the Sensex which declined by 0.92%. The one-month return is even more impressive at 13.73%, compared to a 4.05% decline in the Sensex.

Year-to-date, Sun Pharma has delivered a 10.78% return, while the Sensex has fallen 11.62%. Over the last year, the stock has appreciated by 9.94%, again outperforming the broader market’s negative 8.52% return. Longer-term performance is particularly notable, with a three-year return of 104.99% versus the Sensex’s 22.60%, and a five-year return of 175.78% compared to the Sensex’s 50.05%. Even over a decade, the stock has delivered a strong 139.59% gain, though this trails the Sensex’s 193.00% return over the same period.

Investment Grade and Market Sentiment

MarketsMOJO assigns Sun Pharma a Mojo Score of 78.0 and a Mojo Grade of Buy, a slight downgrade from its previous Strong Buy rating as of 18 May 2026. This reflects a cautious stance given the stretched valuation metrics, despite the company’s solid fundamentals and market leadership in the pharmaceutical sector. The large-cap status of Sun Pharma further supports its appeal as a core portfolio holding, though investors should be mindful of the premium they are paying.

Assessing Price Attractiveness Amid Elevated Valuations

The shift from expensive to very expensive valuation grades signals that Sun Pharma’s stock price has become less attractive on a pure valuation basis. Investors are paying a premium that exceeds historical norms and many peers, particularly when considering the P/E and PEG ratios. While the company’s operational metrics such as ROCE and ROE remain strong, the elevated multiples imply that future earnings growth must be sustained or accelerated to justify current prices.

Given the pharmaceutical sector’s inherent risks, including regulatory challenges, patent expiries, and competitive pressures, the high valuation demands careful scrutiny. The relatively low dividend yield of 0.87% further emphasises that returns are expected primarily through capital appreciation rather than income generation.

However, Sun Pharma’s consistent outperformance relative to the Sensex over multiple time horizons underscores its resilience and growth potential. The stock’s recent price momentum and proximity to its 52-week high suggest continued investor confidence, albeit at a cost.

Conclusion: Balancing Growth Prospects with Valuation Risks

Sun Pharmaceutical Industries Ltd remains a dominant player in the Pharmaceuticals & Biotechnology sector with strong fundamentals and a solid track record of returns. Yet, the recent upgrade in valuation grade to very expensive highlights a shift in price attractiveness that investors must weigh carefully. While the company’s growth prospects and operational efficiency justify a premium, the stretched multiples and high PEG ratio introduce valuation risk that could temper near-term gains.

For investors, the key consideration is whether Sun Pharma can continue to deliver earnings growth that meets or exceeds market expectations embedded in its current price. Those with a longer-term horizon and conviction in the company’s strategic direction may find the stock’s premium valuation acceptable, while more valuation-sensitive investors might await a more attractive entry point or monitor for signs of earnings acceleration.

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today